8-K - PepGen Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

PepGen Inc. announced topline results from the 5 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial, showing PGN-EDODM1 was generally well-tolerated with favorable splicing and vHOT data, supporting the ongoing 10 mg/kg cohort.

Key Takeaways

1PGN-EDODM1 at 5 mg/kg was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported.

2Mean splicing correction was 7.3% for the treatment group versus 6.8% for placebo; excluding one outlier, the treatment group mean was 22.9%.

3Promising trends were observed in video hand opening test (vHOT) in the PGN-EDODM1 treated group.

4The company is on track to report clinical data from the 10 mg/kg multiple dose cohort in the second half of 2026.

5The company expects its cash to fund operations into the second half of 2027.

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

, in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Sectio

Regulation Fd

8.01

Other Events. A copy of the Company’s presentation titled “FREEDOM2-DM1, 5 mg/kg Cohort Data Update”, is filed hereto as Exhibit 99.2 to this Current Report on

Other Event

9.01

Financial Statements and Exhibits. ## (d) Exhibits | Exhibit Number | Description | |---|---| | 99.1 | Press Release dated March 30, 2026 | | 99.2 | FREEDOM2-DM

Exhibits Only

Source Document

Exhibits (3)

8-K

99.1

EX-99.1

99.2

EX-99.2